Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARBOR: Zanidatamab + Tislelizumab + Chemo in HER2+ MIBC
NCT07296705Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab, tislelizumab in muscle-invasive bladder cancer (MIBC), sponsored by Fujian Medical University Union Hospital. Started Oct 2025; status: recruiting.
02
Drugs
zanidatamabtislelizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07296705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07296705.